COVID-19

COVID-19

Newborn Hearing Screenings and Follow-Up: Essential During a Pandemic?

By Shelley Moats and Liza Creel

The primary objective of local, state, and federal response to COVID-19 is to minimize mortality and mitigate explosive demand for acute health-care services related to COVID-19 complications, especially those that require care in intensive care units. 

Read more

Newborn Hearing Screening

ONLINE FEATURE | Newborn Hearing Screenings and Follow-Up: Essential During a Pandemic?

The primary objective of local, state, and federal response to COVID-19 is to minimize mortality and mitigate explosive demand for acute health-care services related to COVID-19 complications, especially those that require care in intensive care units. 

Governmental responses have varied from statewide stay-at-home orders to more incremental approaches targeting restrictions in specific industries and locations. Certainly, many of these restrictions are warranted and necessary to achieve the desired public health outcomes. 

Topic(s): COVID-19, Pediatric Audiology, pediatrics, Early Hearing Detection and Intervention (EHDI), Patient care, tele-audiology

Dietary Supplements with vegetables in the background

ONLINE FEATURE | Dietary Supplements Used for COVID-19 Treatment

There are no dietary supplements that will cure or prevent disease. With the 2019 coronavirus COVID-19 pandemic, it’s especially important to understand that no supplement, diet, or other lifestyle modification other than physical distancing, also known as social distancing, and proper hygiene practices can protect you from COVID-19.

There is no research to support the use of any dietary supplement to protect against COVID-19. No supplement may claim to diagnose, prevent, treat or cure COVID-19. Consumers and retailers should avoid products that suggest they do.1, 2

Topic(s): COVID-19, Ototoxicity, Patient care, diet, dietary supplements

Author(s): 

Publication Issue: Audiology Today May/June 2020

Warren and  Rice Lead Letter to House and Senate Urging Inclusion of Medicare Audiologist Access and Services Act in Upcoming COVID-19 Packages

Senator Elizabeth Warren (D-MA) and Representative Tom Rice (R-SC) led a letter along with Congressman Matt Cartwright (D-PA), Senator Rand Paul (R-KY), Senator Krysten Sinema (D-AZ), Congressman Darren Soto (D-FL), Congressman Gus Bilirakis and Congressman Rodney Davis (R-IL) to House and Senate leadership urging them to include provisions of the Medicare Audiologist Access and Services Act (H.R.4056/S.2446) in upcoming COVID-19 packages to enable vulnerable seniors to readily access critical hearing and balance healthcare services and allow audiologists to be better deployed to provide th

Executive Order Directs Federal Agencies to Recommend COVID-19 Regulatory Waivers 

President Trump signed a new executive order that directs federal agencies to identify and recommend COVID-19 regulatory waivers that should be made permanent. 

CMS has issued numerous waivers and multiple rules to ease regulatory burdens on the health sector during the COVID-19 pandemic.

The newly signed executive order asks federal agencies to look at the waivers they have made and determine “which, if any, would promote economic recovery if made permanent.”

Ototoxicity of FDA-Approved Drugs Being Re-Purposed for COVID-19 Treatment

According to the National Institutes of Health’s Center National Center for Advancing Translational Sciences, many drugs approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation, and potential toxicity. 

Read more

Vestibular Testing Safety: COVID-19 and Beyond

All recommendations are made with the best current information and in the context of a multifaceted safety program. When a variety of safety measures are put in place our chance of protecting our patients and colleagues increases.

All safety recommendations assume that

Read more

Elderly Man with hearing loss

ONLINE FEATURE | Ototoxicity of FDA-Approved Drugs Being Re-Purposed for COVID-19 Treatment

According to the National Institutes of Health’s Center National Center for Advancing Translational Sciences, many drugs approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation, and potential toxicity. 

Topic(s): COVID-19, Ototoxicity, FDA, Patient care, Practice Management

Author(s): 

Publication Issue: Audiology Today May/June 2020

Surgical Monitoring Safety: COVID-19 and Beyond

Because of the potential to aerosolize the virus during drilling in the mastoid cavity, neurotological surgeries present a potentially high risk of contamination. Many audiologists monitor responses during cochlear implant surgeries or may provide intraoperative monitoring for other neurotological surgeries.

All recommendations are made with the best current information and in the context of a multifaceted safety program. When a variety of safety measures are put in place our chance of protecting our patients and colleagues increases.

All safety recommendations assume that

Read more

Booth Safety: COVID-19 and Beyond

All recommendations are made with the best current information and in the context of a multifaceted safety program. When a variety of safety measures are put in place, our chance of protecting our patients and colleagues increases.

All safety recommendations assume that

Read more